Pulmonary Hypertension Due to Left Heart Disease: an Update
- PMID: 31134443
- DOI: 10.1007/s11886-019-1149-1
Pulmonary Hypertension Due to Left Heart Disease: an Update
Abstract
Purpose of review: Pulmonary hypertension (PH) frequently complicates heart failure and portends a worse prognosis. This review will summarize and discuss recent updates in the classification and management of patients with PH due to left heart disease.
Recent findings: Careful hemodynamic assessment is critical to the classification of patients with PH and heart failure. Two hemodynamic subgroups of PH in heart failure patients have been described: isolated post-capillary pulmonary hypertension and combined post- and precapillary pulmonary hypertension. The cornerstone in management of PH due to left heart disease is the treatment of the underlying left heart pathology; however, ongoing trials have been designed to test pulmonary vasodilators in this cohort. PH-specific therapies have not demonstrated a benefit in patients with pulmonary hypertension due to left heart disease. Understanding the distinct pathobiology of each hemodynamic subgroup may lead to the development of useful biomarkers and effective targeted therapies.
Keywords: HFpEF; Heart failure; Left heart disease; Post-capillary; Pulmonary hypertension; WHO group 2 pulmonary hypertension.
Similar articles
-
Management of pulmonary hypertension in left heart disease.Ther Adv Cardiovasc Dis. 2013 Jun;7(3):131-51. doi: 10.1177/1753944713477518. Epub 2013 Apr 16. Ther Adv Cardiovasc Dis. 2013. PMID: 23592742 Review.
-
Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.Curr Heart Fail Rep. 2016 Apr;13(2):92-102. doi: 10.1007/s11897-016-0284-x. Curr Heart Fail Rep. 2016. PMID: 26886381 Review.
-
[Pulmonary hypertension – a common condition in left heart disease].Lakartidningen. 2017 Dec 1;114:ER3E. Lakartidningen. 2017. PMID: 29292958 Review. Swedish.
-
Pulmonary Hypertension secondary to Left Heart Disease.Curr Vasc Pharmacol. 2018;16(6):555-560. doi: 10.2174/1570161115666170913105424. Curr Vasc Pharmacol. 2018. PMID: 28901848 Review.
-
Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction.Cardiovasc Hematol Disord Drug Targets. 2023;23(4):215-225. doi: 10.2174/011871529X258234230921112507. Cardiovasc Hematol Disord Drug Targets. 2023. PMID: 37921162
Cited by
-
microRNA-135a-5p regulates NOD-like receptor family pyrin domain containing 3 inflammasome-mediated hypertensive cardiac inflammation and fibrosis via thioredoxin-interacting protein.Bioengineered. 2022 Mar;13(3):4658-4673. doi: 10.1080/21655979.2021.2024956. Bioengineered. 2022. PMID: 35148667 Free PMC article.
-
Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?Antioxidants (Basel). 2025 Mar 21;14(4):377. doi: 10.3390/antiox14040377. Antioxidants (Basel). 2025. PMID: 40298665 Free PMC article. Review.
-
Pulmonary vasodilator use in continuous-flow left ventricular assist device management.Ann Transl Med. 2021 Mar;9(6):522. doi: 10.21037/atm-20-4710. Ann Transl Med. 2021. PMID: 33850919 Free PMC article. Review.
-
Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.Curr Cardiol Rep. 2019 Nov 22;21(11):141. doi: 10.1007/s11886-019-1235-4. Curr Cardiol Rep. 2019. PMID: 31758342 Review.
-
Progress in Pulmonary Vein Stenosis: Lessons from Success in Treating Pulmonary Arterial Hypertension.Children (Basel). 2022 May 29;9(6):799. doi: 10.3390/children9060799. Children (Basel). 2022. PMID: 35740736 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials